Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 4/20 | 0.47 |
| ▸ | CTSL | P07711 | 3/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6697388 | 1.00 | CTSK (0.57) | CTSKL3MBTL1SCN9AACEITGB3 | |
| SCHEMBL4686404 | 0.92 | CTSK (0.70) | CTSKMAPK1CTSSCTSLCTSB | |
| SCHEMBL4686405 | 0.92 | CTSK (0.70) | CTSKMAPK1CTSSCTSLCTSB | |
| SCHEMBL5105243 | 0.91 | CTSK (0.57) | CTSKITGB3ITGA2BCTSSCTSL | |
| SCHEMBL5105237 | 0.91 | CTSK (0.57) | CTSKITGB3ITGA2BCTSSCTSL | |
| SCHEMBL5983043 | 0.91 | CTSK (0.57) | CTSKITGB3ITGA2BCTSSCTSL | |
| SCHEMBL5983052 | 0.91 | CTSK (0.57) | CTSKITGB3ITGA2BCTSSCTSL | |
| SCHEMBL5099282 | 0.90 | CTSK (0.57) | CTSKITGB3ITGA2BCTSSCTSL | |
| SCHEMBL27537673 | 0.90 | CTSK (0.57) | CTSKITGB3ITGA2BCTSSCTSL | |
| SCHEMBL4791190 | 0.88 | PDE4B (0.54) | CTSKL3MBTL1ITGB3ITGA2BCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192674-A1 | Cathepsin L inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192674-A1 | Cathepsin L inhibitors | CTSE, CTSV, CTSL | CTSK 9/4885L3MBTL1 1119/4885SCN9A 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.